Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.

Wood SM, Shah SS, Steenhoff AP, Meyers KE, Kaplan BS, Rutstein RM.

AIDS Patient Care STDS. 2009 Jan;23(1):1-4. doi: 10.1089/apc.2008.0106. Review.

PMID:
19183077
2.

A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.

Lao CK, Gruta C, John MD, Cocohoba J.

J Natl Med Assoc. 2011 Jun;103(6):518-22.

PMID:
21830636
3.

Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.

Young B, Buchacz K, Moorman A, Wood KC, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2009 Aug;23(8):589-92. doi: 10.1089/apc.2008.0232.

PMID:
19591609
4.

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, Diouf A, Kane CT, Etard JF, Girard PM, Sow PS, Delaporte E; ANRS 1215 Study Group.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1221-7. doi: 10.1089/aid.2009.0261. Epub 2010 Sep 21.

PMID:
20854202
5.

Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study.

Padilla S, Gutiérrez F, Masiá M, Cánovas V, Orozco C.

AIDS Patient Care STDS. 2005 Jul;19(7):421-4.

PMID:
16053398
6.

Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.

Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L.

Trop Med Int Health. 2015 Apr;20(4):518-26. doi: 10.1111/tmi.12446. Epub 2014 Dec 12.

7.

Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.

Agbaji OO, Agaba PA, Idoko JA, Taiwo B, Murphy R, Kanki P, Ekong E.

West Afr J Med. 2011 May-Jun;30(3):164-8.

PMID:
22120479
8.

Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.

Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G; IeDEA-Southern Africa.

Clin Infect Dis. 2014 May;58(10):1473-80. doi: 10.1093/cid/ciu117. Epub 2014 Feb 27.

9.

Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.

Tanaka H, Arai M, Tomoda Y, Wada T, Yago K, Satoh M.

J Pharm Pharm Sci. 2013;16(3):405-13.

10.

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.

Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.

Pediatr Infect Dis J. 2015 Apr;34(4):392-7. doi: 10.1097/INF.0000000000000633. Erratum in: Pediatr Infect Dis J. 2015 Aug;34(8):847.

PMID:
25760566
11.

Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team.

Antimicrob Agents Chemother. 2013 Nov;57(11):5619-28. doi: 10.1128/AAC.01096-13. Epub 2013 Sep 3.

12.

Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.

Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C.

Antivir Ther. 2007;12(1):31-9.

PMID:
17503745
13.

Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.

Johnson DC, Chasela C, Maliwichi M, Mwafongo A, Akinkuotu A, Moses A, Jamieson DJ, Kourtis AP, King CC, van der Horst C, Hosseinipour MC.

PLoS One. 2012;7(7):e41011. doi: 10.1371/journal.pone.0041011. Epub 2012 Jul 27.

14.

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.

Judd A, Boyd KL, Stöhr W, Dunn D, Butler K, Lyall H, Sharland M, Shingadia D, Riordan A, Gibb DM.

AIDS. 2010 Feb 20;24(4):525-34. doi: 10.1097/QAD.0b013e3283333680.

PMID:
20139752
15.

Renal function with use of a tenofovir-containing initial antiretroviral regimen.

Gallant JE, Moore RD.

AIDS. 2009 Sep 24;23(15):1971-5. doi: 10.1097/QAD.0b013e32832c96e9.

16.

Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Jafari A, Khalili H, Dashti-Khavidaki S.

Eur J Clin Pharmacol. 2014 Sep;70(9):1029-40. doi: 10.1007/s00228-014-1712-z. Epub 2014 Jun 25. Review.

PMID:
24958564
17.

The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.

Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL.

Nephrol Dial Transplant. 2013 Aug;28(8):2073-81. doi: 10.1093/ndt/gft210. Epub 2013 Jun 5.

PMID:
23739150
18.

Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.

Della Negra M, De Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MT, Andreatta KN, Graham B, Liu YP, Quirk EK.

Pediatr Infect Dis J. 2015 Apr;34(4):398-405. doi: 10.1097/INF.0000000000000649.

PMID:
25599284
19.

Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.

Woratanarat K, Kanjanabuch T, Suankratay C.

J Med Assoc Thai. 2013 Apr;96(4):432-9.

PMID:
23691697
20.

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S.

BMC Infect Dis. 2012 Jan 23;12:18. doi: 10.1186/1471-2334-12-18.

Supplemental Content

Support Center